ABBOTT LABORATORIES Decrease in Unrecognized Tax Benefits is Reasonably Possible
ABBOTT LABORATORIES (ABT) had Decrease in Unrecognized Tax Benefits is Reasonably Possible of $90.00 million as of 2024-06-30, per its 10-Q filed 2024-07-31.
Discontinued › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible · last filed 2024-07-31
- 2024-06-30: Decrease in Unrecognized Tax Benefits is Reasonably Possible $90.00M.
- 2024-03-31: Decrease in Unrecognized Tax Benefits is Reasonably Possible $82.00M.
- 2023-09-30: Decrease in Unrecognized Tax Benefits is Reasonably Possible $55.00M.
- 2023-06-30: Decrease in Unrecognized Tax Benefits is Reasonably Possible $100.00M.
| Period end | Decrease in Unrecognized Tax Benefits is Reasonably Possible |
|---|---|
| 2024-06-30 | $90.00M 10-Q · filed 2024-07-31 |
| 2024-03-31 | $82.00M 10-Q · filed 2024-05-02 |
| 2023-09-30 | $55.00M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $100.00M 10-Q · filed 2023-08-03 |
| 2022-12-31 | $315.00M 10-K · filed 2023-02-17 |
| 2021-09-30 | $80.00M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $80.00M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $50.00M 10-Q · filed 2021-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |